Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €4.24 EUR
Change Today +0.05 / 1.19%
Volume 617.9K
ZEL On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
Continuous
OTC US
As of 11:38 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

zeltia sa (ZEL) Snapshot

Open
€4.19
Previous Close
€4.19
Day High
€4.25
Day Low
€4.18
52 Week High
04/15/15 - €4.28
52 Week Low
10/16/14 - €2.33
Market Cap
942.1M
Average Volume 10 Days
703.8K
EPS TTM
€0.06
Shares Outstanding
222.2M
EX-Date
07/15/11
P/E TM
71.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for ZELTIA SA (ZEL)

Related News

No related news articles were found.

zeltia sa (ZEL) Related Businessweek News

No Related Businessweek News Found

zeltia sa (ZEL) Details

Zeltia, S.A. operates in the biopharmaceutical industry and consumer chemical sectors. It researches, develops, produces, and markets various types of bioactive products of marine origin for application in oncology; and products with therapeutic activity based on reducing or silencing gene expression and pharmaceutical derivatives of same in a range of formulations, as well as develops and markets biopharmaceutical applications, diagnosis, and related services. The company’s products include Yondeli, a marketed product for the treatment of ovarian cancer and soft tissue sarcoma; Aplidi, which is in Phase III trials for the treatment of multiple myeloma, as well as in angioimmunoblastic Tcell lymphoma; Zalypsi that is in Phase II trials for the treatment of multiple myeloma; PM1183, which has completed Phase IIb trials for the treatment of platinum-refractory/resistant ovarian cancer; PM060184 that is in Phase I trials for the treatment of various types of tumors; and SYL040012, which is in Phase IIB clinical trials for the treatment of glaucoma. It also develops and markets diagnosis kits. In addition, the company is involved in the manufacture and sale of wood and metal protective and decorative products, paints, and other related products; manufacture and marketing of domestic and industrial insecticides and air fresheners for household use; manufacture and sale of automatic aerosol dispensers under the Copyrmatic brand; and production of products for ecological farming. Further, it provides services for treating and protecting wood, and repairing and preserving structures, as well as insect control and disinfection services. Zeltia, S.A. was founded in 1939 and is headquartered in Madrid, Spain.

Founded in 1939

zeltia sa (ZEL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zeltia sa (ZEL) Key Developments

Zeltia SA Reports Earnings Results for the Full Year 2014

Zeltia SA reported earnings results for the full year 2014. For the year, the company reported group total revenues amounted to EUR 178 million up 8% with respect to EUR 164.7 million in 2013. Group EBITDA amounted to EUR 25.7 million, up 8% year-on-year. This improvement in operating profit was achieved despite the increase in R&D spending, which amounted to EUR 52.5 million in 2014, up 23% year-on-year. Of that figure, EUR 45.3 million corresponds to the oncology area. net attributable profit amounted to EUR 13.1 million, compared with EUR 11.3 million in 2013 (+16%).

Zeltia SA Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Zeltia SA Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Zeltia Reports Earnings Results for the Nine Months Ended September 2014

Zeltia reported earnings results for the nine months ended September 2014. For the period, the company's net sales grew by 7% year on year to EUR 116.9 million. Net profit amounted to EUR 17.5 million, a 24.3% increase compared with the same period in 2013. Positive performance was driven mainly by star oncology product Yondelis (trabectedin), net sales of which reached EUR 57 million, and the net sales of Biofarmacia increased by 7% to EUR 61.2 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEL:SM €4.24 EUR +0.05

ZEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEL.
View Industry Companies
 

Industry Analysis

ZEL

Industry Average

Valuation ZEL Industry Range
Price/Earnings 63.8x
Price/Sales -- Not Meaningful
Price/Book 13.1x
Price/Cash Flow 64.6x
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZELTIA SA, please visit www.zeltia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.